BACKGROUND: Hypersensitivity pneumonitis (HP) is an interstitial lung disease with a better prognosis, on average, than idiopathic pulmonary fibrosis (IPF). We compare survival time and pulmonary function trajectory in patients with HP and IPF by radiologic phenotype.
Hypersensitivity pneumonitis (HP) is a heterogeneous interstitial lung disease (ILD) caused by inhalational exposure to a variety of antigens. 1 Patients with HP and radiologic or histopathologic evidence of pulmonary fibrosis experience shortened survival compared with those without pulmonary fibrosis. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Sometimes called chronic HP, these patients can have similar histopathologic and radiologic manifestations as those with idiopathic pulmonary fibrosis (IPF), 11 including a usual interstitial pneumonia (UIP)-like pattern of fibrosis on lung biopsy 5, 10, 12, 13 and honeycomb cysts on high-resolution CT (HRCT) scan. 3, 14, 15 Disease chronicity has been variably defined by duration of symptoms or evidence of pulmonary fibrosis on radiologic imaging or lung biopsy.
Despite overlap in presenting features, HP is considered to have a better prognosis than IPF. Several studies suggest that chronic HP has a longer survival time than IPF. 4, 6 In contrast, when the clinical diagnosis of HP is defined by antigen exposure, patients with HP with a histopathologic UIP-like pattern have outcomes similar to unexposed UIP/IPF, 6 including a median survival of 3.6 to 4.2 years, 5, 10 well within the range reported for IPF. 11 We sought to develop a radiologic phenotype classification associated with lung transplant-free survival and postdiagnosis pulmonary function trajectory in patients with HP. We also compare outcomes in patients with HP and IPF by radiologic phenotype. We hypothesized that after accounting for radiologic phenotype, the specific ILD diagnosis (ie, HP, IPF) provides little incremental prognostic information.
Methods

Patient Selection
Review of the University of Michigan's multidisciplinary ILD conference 16 minutes (February 1, 2009-August 31, 2014) and searching "hypersensitivity pneumonitis" International Classification of Diseases, 9th revision codes (495.7, 495.8, 495.9) (January 1, 2004-December 31, 2013) identified subjects. ILD diagnoses were verified by detailed chart review. Supporting evidence for HP diagnosis verification included a surgical biopsy reviewed by a University of Michigan pathologist as consistent with HP such that no differential diagnosis was provided (termed classic HP) (e- Table 1 ), or at least two of the following: BAL lymphocytosis > 20%, consistent transbronchial or surgical biopsy findings (loose nonnecrotizing granulomas, giant cells, mononuclear inflammatory interstitial or peribronchiolar infiltrate named in report, or HP listed in differential diagnosis), or plausible exposure history (e- Table 1) . 1 e- Table 2 provides a detailed overview of supporting evidence of HP in those subjects not diagnosed via a classic HP surgical biopsy. All IPF cases had a surgical biopsy. 11, 17 Figure 1 shows the numbers of screened patients and reasons for exclusion. Clinical characteristics were collected from the medical record. FVC % predicted, FEV 1 % predicted, and diffusion capacity for carbon monoxide % predicted were measured. [18] [19] [20] The date of lung transplantation or death without transplant was verified by medical record and the National Death Index (complete through December 31, 2016) . The institutional review board at the University of Michigan approved this study (No. HUM00093978). Some results were presented as an abstract, 21 and this cohort overlaps with a prior publication.
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HRCT Scan Interpretation
Interpretation methods are presented in e- Figure 1 and e-Appendix 1. Briefly, three radiologists reviewed HRCT scans. Radiologic features of honeycombing, reticular pattern, ground glass, mosaic attenuation, and air trapping (when expiratory images were available) 23 were scored semi-quantitatively in each of five lobes, and lobar scores were summed and divided by five for an average (scale, 0-5). Traction bronchiectasis and centrilobular nodules were recorded as present (score ¼ 1) or absent (score ¼ 0) in each lobe and summed to represent the number of lobes having the feature. A three-reader consensus average was created for semi-quantitatively scored variables. A dichotomous variable for each feature was present if the three-reader average/sum was > 0.5. The craniocaudal distribution of disease was upper, lower, or diffuse. Axial distribution was noted as central, peripheral, subpleural, peribronchovascular, or diffuse.
Statistical Methods
Analyses were via SAS 9.4 (SAS Institute) and R 3.2.1 (The R Foundation). Baseline clinical and HRCT scan characteristics are shown as mean AE SD, median (range), or number (%), with comparison of characteristics in subjects with HP with subjects with IPF via t test, rank-sum test, c 2 test, or Fisher exact test, as appropriate. Methods for measuring interobserver agreement on HRCT scan characteristics is presented in e-Appendix 1.
Survival time is calculated from the HRCT scan to composite death or lung transplant, with nonevents censored on December 31, 2016. Cox proportional hazards models assess association of predictors with survival time. To compare survival time in patients with HP with patients with IPF by radiologic phenotype and test our hypothesis that after accounting for radiologic phenotype the specific ILD diagnosis (ie, HP, IPF) provides little incremental prognostic information, we used a multivariable Cox proportional hazards model with one term capturing the radiologic phenotype-clinical diagnosis interaction. We then compared the interaction model to models with radiologic phenotype alone, clinical diagnosis alone, and adjustment variables (age, sex, FVC % predicted) alone. The index of concordance (c statistic) gives model discrimination. 24 P values comparing c statistics are done via the bootstrap method. The partial likelihood ratio test (LRT) identified the most parsimonious nested model with the best fit. 25 Cox model-based survival estimates with baseline hazards stratified by radiologic phenotype and clinical diagnosis, and typical patient profile assumed (age, 61.9 years; sex, 51% women; FVC % predicted, 65.6), are plotted to show adjusted transplant-free survival probability.
Mixed effects models estimate FVC % predicted change over 12 months based on clinical diagnosis and radiologic phenotype, adjusted for baseline age and sex. The baseline test was dated closest 1,664 Individuals from multidisciplinary ILD conference February 1, 2009 to August 31, 2014 415 separate individuals evaluated in UM pulmonary clinics with "HP" ICD-9 codes January 1, 2004 to December 31, 2013 Identified Well-Characterized ILD: N = 361 -HP N = 121 (33.7%); 45 via ILD conference; 76 from ICD-9 search*** -Control N = 240 (66.3%); 219 from conference; 21 from ICD-9 search*** detailing included subjects and exclusion criteria. *Includes those with ILD diagnosis confirmed by HRCT scan only (ie, definite usual interstitial pneumonia HRCT scan pattern) and those unwilling or unable to undergo diagnostic biopsy. **Excluded diagnoses include primary cystic lung disease, pulmonary alveolar proteinosis, airway or pulmonary vascular disease without ILD, drug-induced lung disease, infection, and other non-ILD diagnoses (congestive heart failure, etc). ***Of included patients identified from the ICD-9 search alone, 23 HP and 7 control patients had chart documentation of multidisciplinary case review, which occurred prior to creation of a searchable database of conference minutes. AIP ¼ acute interstitial pneumonitis; COP ¼ cryptogenic organizing pneumonia; CTD-ILD ¼ connective tissue disease-associated ILD; DIP ¼ desquamative interstitial pneumonia; HP ¼ hypersensitivity pneumonitis; HRCT ¼ high-resolution CT; ICD-9 ¼ international classification of diseases, 9th revision; ILD ¼ interstitial lung disease; IPF ¼ idiopathic pulmonary fibrosis; NSIP ¼ nonspecific interstitial pneumonia; PLCH ¼ pulmonary Langerhans cell histiocytosis; RB-ILD ¼ respiratory bronchiolitis-ILD.
chestjournal.org in time to the HRCT scan. Mixed models account for loss to follow-up because of attrition using all available data measured prior to the loss to follow-up time. Hence, all 269 subjects were included in the model regardless of availability of postbaseline FVC % predicted measurements through 12 months. FVC % predicted measurements recorded after lung transplant were censored, and those recorded > 24 months postbaseline were removed to mitigate survivorship bias.
Results
Patient and HRCT Scan Characteristics
Patients with HP (mean age AE SD, 58.3 AE 11.0 years) were younger than those with IPF (mean age AE SD, 64.7 AE 8.21), less likely to be men (32% of those with HP vs 62% of those with IPF), more likely to be neversmokers (53% of those with HP vs 39% of those with IPF), and more likely to have received corticosteroids prior to evaluation at the University of Michigan (38% of those with HP vs 18% of those with IPF). Baseline FVC % predicted and diffusion capacity for carbon monoxide % predicted were similar (Table 1) . Median time between the baseline pulmonary function test and HRCT scan was 7 days. e- Tables 3-6 provide detailed information about HRCT scan quality, protocols, and interrater agreement across three radiologists. As shown in Table 2 , HP compared with IPF had more radiologic ground glass, mosaic attenuation, air trapping, and centrilobular nodules and less honeycombing, reticulation, and traction bronchiectasis. HP compared with IPF were more likely to have a diffuse or upper lung craniocaudal disease distribution, and diffuse axial disease distribution.
HRCT Scan Phenotype and Transplant-Free Survival
There were 137 events during 7.36 (95% CI, 6.90-8.21) median follow-up years, including 103 deaths (HP: n ¼ 34, IPF: n ¼ 69) and 34 transplants (HP: n ¼ 9, IPF: n ¼ 25). To develop an HRCT scan phenotype associated with survival in patients with HP, the unadjusted association of clinical, physiologic, and radiologic characteristics with lung transplant-free survival in patients with HP and IPF were evaluated (Table 3 ). In patients with HP, presence of fibrotic features of honeycombing (hazard ratio [HR], 7.95; 95% CI, 3.94-16.10; P < .001), traction bronchiectasis (HR, 3.80; 95% CI, 1.68-8.57; P ¼ .001), and reticulation (HR, 9.85; 95% CI, 4.08-23.74; P < .001) were associated with shorter survival; similar effects were observed with greater extent of these features. Three mutually exclusive radiologic phenotypes were created based on unadjusted analysis. The honeycomb phenotype is defined by presence of any honeycombing, regardless of other radiologic features.
Non-honeycomb fibrosis (termed fibrotic) is defined by absence of honeycombing but presence of traction bronchiectasis and reticulation. Both features define the fibrotic phenotype because of the greater weight of reticulation as a predictor of poor outcome and better interobserver agreement on presence of traction bronchiectasis (e-Tables 4, 6). Subjects with the nonfibrotic phenotype did not meet criteria for either of the previously described phenotype groups. e- Table 7 shows relevant baseline demographics, diagnostic criteria, pulmonary function, and semiquantitative HRCT scan feature scores and post-HRCT scan treatments rendered, by HRCT scan phenotype for subjects with HP. e- Table 8 shows similar data for subjects with IPF.
To determine if clinical diagnosis yielded prognostic information beyond the radiologic phenotype, a series of multivariable Cox models were assessed (Table 4) . chestjournal.org model) had significantly better fit and discrimination (c statistic, P < .001; partial LRT, P < .001).
Using model 4, transplant-free survival time was compared by diagnosis and phenotype group (Fig 2,  Table 5 ). Within subjects with HP, radiologic phenotype group had distinct survival times: patients with nonfibrotic HP survive longer than those with fibrotic HP (HR, 0.22; 95% CI, 0.10-0.51; P < .001) and honeycomb HP (HR, 0.06; 95% CI, 0.02-0.15; P < .001), and subjects with fibrotic HP survive longer than those with honeycomb HP (HR, 0.26; 95% CI, 0.12-0.54; P < .001). Similarly, subjects with fibrotic IPF survive longer than those with honeycomb IPF (HR, 0.59; 95% CI, 0.37-0.95; P ¼ .03). Within the fibrotic phenotype, subjects with HP had significantly longer survival than those with IPF (HR, 0.46; 95% CI, 0.27-0.77; P ¼ .003). In a separate model including only subjects with the fibrotic phenotype, an IPF Semi-quantitative scores: For honeycombing, reticulation, ground glass, mosaic attenuation, and air trapping, the average score was determined by summing five lobe scores and dividing by five for each subject and each radiologist/reader. For centrilobular nodules and traction bronchiectasis, the sum was determined by adding the score for five lobes. The three radiologist's scores were then averaged. Average and sum scores are scaled from 0 to 5, corresponding to the proportion of total lung having the feature (for honeycombing, reticulation, ground glass, mosaic attenuation, air trapping) or number of lobes having the feature (centrilobular nodules, traction bronchiectasis). Dichotomous scores: A feature was designated as absent when the three-reader average score (for honeycombing, reticulation, ground glass, mosaic attenuation, air trapping) or sum score (centrilobular nodules, traction bronchiectasis) for that features was < 0.5, otherwise the feature was considered present.
diagnosis was associated with shortened survival (HR, 1.45; 95% CI, 0.88-2.97; P ¼ .13) after adjusting for fibrosis extent using the traction bronchiectasis score, age, sex, and FVC % predicted (e- Table 9 ); however, the effect did not reach statistical significance. Within the honeycomb phenotype, subjects with HP had (Table 5) . In a separate model evaluating only subjects with the honeycomb phenotype, this conclusion was robust after adjusting for traction bronchiectasis score, age, sex, and baseline FVC % predicted (e -Table 10 ).
HRCT Scan Phenotype and Pulmonary Function Trajectory
In total, 269 subjects had 1,159 FVC % predicted measurements, with a mean 4.3 measurements per subject (range, 1-15). A total of 220 subjects had at least two measurements. In unadjusted analysis, subjects who were nonfibrotic had a higher baseline FVC % predicted than other groups (e- Tables 7, 8 ). In adjusted FVC % predicted trajectory analyses for 12 months postbaseline (Fig 3) , subjects with nonfibrotic HP experienced a 1.92% gain in FVC % predicted (95% CI, 0.49-3.35; P ¼ .009). Subjects with fibrotic HP (À1.65; 95% CI, À3.19 to À0.10; P ¼ .04) and honeycomb HP (À6.80%; 95% CI, À10.57 to À3.04; P < .001) had declining FVC % predicted. Aside from one subject with radiologically nonfibrotic IPF, subjects with IPF experienced pulmonary function decline: fibrotic by À3.86% (95% CI, À4.83 to À2.89; P < .001) and honeycomb by À4.13% (95% CI, À6.39 to À1.87; P < .001).
Discussion
In a cohort of subjects with HP and IPF, we identified three radiologically defined phenotypes among subjects with HP. Phenotype groups have distinct postdiagnosis survival time and pulmonary function trajectory. Radiologic honeycombing is associated with the shortest median survival (2.8 years) in HP, similar to honeycomb IPF (2.8 years). HP subjects with non-honeycomb fibrosis had intermediate survival (7. 95 years), significantly better than those with fibrotic IPF (5.2 years). HP subjects without radiologic fibrosis survived longest (> 14.7 years) and experienced significant 12-month improvement in FVC % predicted. Knowledge of clinical diagnosis in addition to radiologic phenotype resulted in statistically significant improvement in fit of a Cox proportional hazards model, likely driven by longer survival among subjects with fibrotic HP vs subjects with fibrotic IPF. Given the uniformly poor outcome among subjects with radiologic honeycombing, pursuit of invasive diagnostic tests directed at differentiating IPF from HP may be of limited value. Conversely, subjects with non-honeycomb fibrosis HP had significantly longer survival than subjects with IPF despite both demonstrating radiologic non-honeycomb fibrosis, underlining the importance of assigning the correct clinical diagnosis in patients with non-honeycomb fibrosis on HRCT scan. Despite longer survival among patients with HP, patients with fibrotic HP and IPF had a similar 12-month FVC % predicted decline.
IPF-nonfibrotic (n
Numerous analyses highlight the prognostic value of identification and/or quantification of radiologic fibrosis among patients with HP. 3, 4, 26, 27 Mooney et al 4 found that greater extent of radiologic fibrosis (measured semi-quantitatively) is associated with shortened transplant-free survival among patients with HP. Here, a clinical diagnosis of IPF and radiologic fibrosis score were independent predictors of increased hazard of death/transplant. Our results are in line with those of Mooney et al, but suggest there is value in separating subjects with radiologic honeycombing from those with non-honeycomb fibrosis given a particularly poor prognosis in the face of radiologic honeycombing, a reliable marker of histopathologic UIP. 11 Perez-Padilla et al 6 compared
survival among bird-exposed subjects with HP (ie, those with histopathologic findings of interstitial/ peribronchiolar mononuclear inflammation and giant cells/loose nonnecrotizing granuloma), bird-exposed subjects with biopsy-proved UIP, and unexposed chestjournal.org subjects with UIP/IPF. Survival among bird-exposed and unexposed UIP was nearly identical, with subjects with biopsy-proved HP surviving significantly longer than subjects with UIP. 6 Survival analyses comparing Importantly, radiologic honeycombing was defined in this study as a three-reader averaged semi-quantitative honeycombing score > 0.5. Therefore, some subjects in the non-honeycomb groups may have had minimal honeycombing (eg, involving # 5% of a lobe) as noted by one or more readers. Indeed, as showed in e- Table 7 among the subjects with fibrotic HP, the average semiquantitative score for honeycombing was 0.04, and in e- Table 8 among subjects with fibrotic IPF, the average semi-quantitative score for honeycombing was 0.09.
Chung et al 26 evaluated the prognostic value of various radiologic features and found that presence of radiologic fibrosis (including honeycombing) is associated with significantly increased hazard of death among HP. Another relevant finding in that study is an association of mosaic attenuation or air trapping with reduced hazard of death. In our study, in the HP cohort, dichotomized mosaic attenuation or air trapping was associated with a nonsignificantly reduced hazard of death/transplant. Lack of power in our study or different accounting for transplant events in survival models could explain discrepant results. Our study has weaknesses. First, requiring a lung biopsy for IPF diagnosis may select subjects with atypical clinical or radiologic features compared with IPF all-comers. However, we deemed this bias more suitable than the alternative of including uncertain IPF diagnoses (ie, unbiopsied IPF), given the research question. Of note, IPF with honeycombing has less extensive ground glass, mosaic attenuation, air trapping, and centrilobular nodules than fibrotic IPF (e -Table 8) , mitigating concern about atypical CT scan features. Second, subjects with HP and IPF referred to our quaternary center may differ systematically compared with the broader population (eg, referral for diagnostic/treatment dilemma). Third, these results should be verified in an independent cohort prior to broad clinical application. Fourth, we do not specifically account for postdiagnosis treatment effects on survival or pulmonary function change. Patients with fibrotic or honeycomb HP were more likely to receive immunosuppressant therapy than patients with IPF, and patients with IPF were more likely to receive antifibrotic or no therapy compared with HP. In the nonfibrotic HP group, only 13% received no treatment after diagnosis.
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In conclusion, we identify three radiologically defined subgroups of patients with HP with unique prognoses.
Those not meeting our radiologic criteria for pulmonary fibrosis (based on absence of radiologic honeycombing and traction bronchiectasis/ reticulation) experienced improving pulmonary function in 12 months after diagnosis and had significantly longer lung transplant-free survival than other subjects with HP. Those with fibrotic HP but no radiologic honeycombing had longer survival than patients with fibrotic IPF, but experienced a 12 month decline in pulmonary function. Those with radiologic honeycombing had poor median survival and declining The plot shows that patients with hypersensitivity pneumonitis without radiologic fibrosis have significant increase in FVC % predicted, whereas all other groups experience a significant decrease in FVC % predicted. The group of subjects with idiopathic pulmonary fibrosis without fibrosis was small (n ¼ 1) making comparisons difficult. The plot is adjusted for a typical age (61.9 y) and sex (51% women) profile. The baseline FVC % predicted location is therefore slightly different than the unadjusted values by diagnosis and phenotype group cited in the text.
chestjournal.org FVC % predicted regardless of clinical diagnosis. These results highlight the importance of making a correct diagnosis of HP (vs IPF) in patients with non-honeycomb fibrosis and the limited utility in differentiating HP from IPF among patients with radiologic honeycombing.
